Breakthrough Drug to Treat Multiple Sclerosis Wins FDA Approval

Studies found that Ocrevus was highly effective for patients with relapsing-remitting MS, reducing the number of episodes by half. The drug, however, costs $65,000 a year — pricey but still less expensive than current medications on the market.